Dr. Jean-Claude Tardif


Title(s), professional position(s) and university affiliation(s): 

Director, Research Center, Montreal Heart Institute

Jean-Claude Tardif
  • Scientific Director, Montreal Heart Institute Coordinating Center (MHICC)
  • Full Professor, Faculty of Medicine, Université de Montréal
  • Canada Research Chair in Translational and Personalized Medicine
  • Pfizer Chair in Atherosclerosis, Université de Montréal
  • Chair, Steering Committee, Canadian Atherosclerosis Imaging Network (CAIN)
  • President, Medical Imaging Trial Network of Canada (MITNEC)

Jean-Claude Tardif is the Director of the Montreal Heart Institute Research Centre and a full professor of medicine at Université de Montréal. He received his degree in medicine from Université de Montréal in 1987, completed his residency in cardiology in 1992, and did a research fellowship at the New England Medical Center at Tufts University in 1994.  He has published over 700 articles and research abstracts in major scientific journals, such as: The New England Journal of Medicine, the Journal of the American Medical Association, The Lancet, Circulation, the Journal of the American College of Cardiology, Nature Genetics, the British Journal of Pharmacology, and Cardiovascular Research. He has written over 30 book chapters (including a chapter in Braunwald's Heart Disease). To date, he has given over 400 lectures around the world. His research activities cover the molecular, genomic and clinical aspects of atherosclerosis and related diseases and have involved key contributions to preclinical studies and major international randomized clinical trials. He created the Montreal Heart Institute Coordinating Center (MHICC), which has an international reputation. Dr. Tardif and his team also created the Beaulieu-Saucier Pharmacogenomics Centre and the Centre of Excellence in Personalized Medicine (Cepmed), which receives ongoing support from multiple pharmaceutical and biotech companies. He is also one of the three founders of an international partnership on biomarkers called Critical Markers of Disease ( CMOD, www.cmod.org), an organization that focuses on the development and enhanced use of biomarkers while facilitating international networking in this important field. Dr. Tardif's scientific contributions earned him the title of Fellow of the Canadian Academy of Health Sciences along with the Prix du Québec, the province's highest scientific honour.

Research interest(s) 

Cardiovascular diseases
Vascular imaging
Personalized medicine

Awards and Distinctions 

Pfizer Chair in Atherosclerosis, Université de Montréal
Canada Research Chair in Translational and Personalized Medicine
Genesis Award, BIOQuébec, 2011
Prix Armand-Frappier, Government of Quebec, 2011
La Presse personality of the week, 2008
Fellow, Canadian Academy of Health Sciences, 2007
Research Achievement Award, Canadian Cardiovascular Society, 2008

Contact informations